<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00299611</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00008596</org_study_id>
    <nct_id>NCT00299611</nct_id>
  </id_info>
  <brief_title>Augmentation Study of Levetiracetam in Obsessive Compulsive Disorder</brief_title>
  <official_title>A Double-Blind Augmentation Study of LEvetiracetam in Obsessive Compulsive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effectiveness of Levetiracetam augmentation
      relative to Placebo in SSRI non-remitters with obsessive compulsive disorder. The hypothesis
      is that anxiolytic effect of Levetiracetam is more beneficial when adding with a SSRI.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an investigator-initiated, single-site study, consisting of two phases: 8 weeks of
      open-label treatment with sertraline (50mg-150mg/day) in patients iwth OCD.At week 8, those
      who have failed to achieve remission will be continued on sertraline and will be randomized
      to receive Levetiracetam (500mg-2000mg/day) or Placebo for 8 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor decided to terminate the study due to budget consideration
  </why_stopped>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Global Impression-improvement (CGI-I)</measure>
    <time_frame>24 wks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Yale-Brown Obsessive-Compulsive Scale (YBOCS)</measure>
    <time_frame>24 wks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Anxiety and Depression Scale</measure>
    <time_frame>24 wks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sheehan Disability Scale (SDS)</measure>
    <time_frame>24 wks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Obsessive-Compulsive Disorder</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Levetiracetam</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>there is no active ingredient in the pills.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sertraline</intervention_name>
    <description>Tablets, 50mg each, (1-3TABLETS/DAY) during the Open-label phase for first 8 wks.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Zoloft</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levetiracetam</intervention_name>
    <description>Tablets, dosage 500mg each tablet (1-4tablets/day)for 8 wks during the 2nd phase of the study.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Keppra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablets, No active ingredient, (1-4tablets/day) for 8 wks during the 2nd phase of the study.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ages 18-65

          -  primary diagnosis of OCD based on DSM-IV criteria and assessed by the MINI
             International Neuropsychiatric Interview

          -  Yale-Brown Obsessive-Compulsive Scale (YBOCS) score of at least 16 or greater on
             screening

          -  Ability to provide written consent form

        Exclusion Criteria:

          -  Any primary DSM-IV Axis I disorder other than OCD

          -  Substance abuse during the last 6 months

          -  A clinically unstable medical condition or clinically significant laboratory
             abnormalities

          -  Suicidal risk or serious suicidal attept during the last year

          -  Concurrent use of psychotropic medication including benzodiazepines, barbituates,
             antiepileptic drugs, antidepressants, buspirone, dietary supplements or herbal or
             homeopathic remedies with psychotropic effects

          -  Recent (within the last 3 months) initiation of cognitive behavioral therapy

          -  Failure of previous trial of levetiracetam at 2000 mg/day

          -  Pregnancy or lactation

          -  Women of childbearing potential who are unwilling to practice an acceptable method of
             contraception
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei Zhang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://dukehealth.org</url>
  </link>
  <link>
    <url>http://clinicaltrials.gov</url>
  </link>
  <reference>
    <citation>Ellingrod VL. Pharmacotherapy of primary obsessive-compulsive disorder: review of the literature. Pharmacotherapy. 1998 Sep-Oct;18(5):936-60. Review.</citation>
    <PMID>9758307</PMID>
  </reference>
  <reference>
    <citation>Sasson Y, Zohar J, Chopra M, Lustig M, Iancu I, Hendler T. Epidemiology of obsessive-compulsive disorder: a world view. J Clin Psychiatry. 1997;58 Suppl 12:7-10. Review.</citation>
    <PMID>9393390</PMID>
  </reference>
  <reference>
    <citation>Steketee G. Disability and family burden in obsessive-compulsive disorder. Can J Psychiatry. 1997 Nov;42(9):919-28. Review.</citation>
    <PMID>9429061</PMID>
  </reference>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2006</study_first_submitted>
  <study_first_submitted_qc>March 6, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2006</study_first_posted>
  <last_update_submitted>April 9, 2013</last_update_submitted>
  <last_update_submitted_qc>April 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 11, 2013</last_update_posted>
  <responsible_party>
    <name_title>Wei Zhang/ Director of Anxiety and Traumatic Stress Program</name_title>
    <organization>DUMC</organization>
  </responsible_party>
  <keyword>OCD</keyword>
  <keyword>Anxiety</keyword>
  <keyword>Pharmacotherapy</keyword>
  <keyword>Sertraline</keyword>
  <keyword>Levetiracetam</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Compulsive Personality Disorder</mesh_term>
    <mesh_term>Obsessive-Compulsive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sertraline</mesh_term>
    <mesh_term>Etiracetam</mesh_term>
    <mesh_term>Piracetam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

